PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Benzydamine→

Benzydamine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
642-72-8
Molecular formula
C19H23N3O
Molecular weight
309.4 g/mol
Drug class
Topical indazole anti-inflammatory and analgesiclocal anaesthetic activity
Mechanism of action
Acts mainly through local anti-inflammatory effects, including inhibition of pro-inflammatory cytokine synthesis (notably TNF-α and IL-1β), membrane stabilisation and reduced neutrophil oxidative/granule responses. It is only a weak cyclo-oxygenase/lipoxygenase inhibitor at higher concentrations and also has local anaesthetic activity.
Indications / reported uses
  • Short-term local relief of pain and inflammation in the mouth and throat, including sore throat, pharyngitis, tonsillitis, oral ulcers and inflammation following dental procedures; formulation-specific use applies

Sources: UK SmPC — Benzydamine 0.15% oromucosal spray · NHS medicine information — Benzydamine · Peer-reviewed pharmacology review (2025) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Benzydamine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Benzydamine Permitted Daily Exposure (PDE) report (the Benzydamine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Benzydamine Occupational Exposure Limit (OEL) report (the Benzydamine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.